Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- S&P 500, Nasdaq futures tick up as tech steadies, Micron earnings eyed
- Brent extends losses on expectations of smoother crude flows via Hormuz
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Needham Starts NeoVolta (NEOV) at Buy
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
UPDATE: Eagle Pharmaceuticals (EGRX) Reports Q4 EPS of 48c
March 2, 2020 6:51 AM EST(Updated - March 2, 2020 6:52 AM EST)
Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q4 EPS of $0.48 vs the analyst estimate of $0.49. Revenue for the quarter came in at $48.3 million versus the consensus estimate of $49.07 million.
2020 Expense Guidance
R&D spend in 2020, on a... More